Determination of the safety and efficacy of therapeutic neutralization of tumor necrosis factor-α (TNF-α) using AZD9773, an anti-TNF-α immune Fab, in murine CLP sepsis

Inflammation Research

Volumn 63, Issue 2, 2014, Pages 149-160

  Newham, Peter ^a   Ross, Daniel ^b   Ceuppens, Peter ^a   Das, Shampa ^a   Yates, James W T ^a   Betts, Catherine ^a   Reens, Jaimini ^a   Randall, Kevin J ^a   Knight, Richard ^a   McKay, Jennifer S ^a,c  

^a ASTRAZENECA   (United Kingdom)

^b TransPharm Preclinical Solutions   (United States)

^c IDEXX LABORATORIES   (United Kingdom)

Author keywords

AZD9773; CLP; Pharmacokinetics; Sepsis; Tg1278; TNF

Indexed keywords

ANIMALS; CECUM; CYTOKINES; IMMUNOGLOBULIN FAB FRAGMENTS; LIGATION; LIPOPOLYSACCHARIDES; LIVER; MALE; MICE; MICE, TRANSGENIC; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84895075439     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-013-0683-3     Document Type: Article

References (37)

1. Perl TM, Dvorak L, Hwang T, Wenzel RP. Long-term survival and function after suspected gram-negative sepsis. JAMA. 1995;274:338-45.
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546-54. (Pubitemid 36437931)
3. Sharma VK, Dellinger RP. Treatment options for severe sepsis and septic shock. Expert Rev Anti Infect Ther. 2006;4:395-403. (Pubitemid 43905462)
4. Schuerholz T, Marx G. Management of sepsis. Minerva Anestesiol. 2008;74:181-95. (Pubitemid 351895337)
5. Blackwell TS, Christman JW. Sepsis and cytokines: current status. Br J Anaesth. 1996;77:110-7. (Pubitemid 26229918)
6. Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, Lee AT, Kuo GC, Allison AC, Lowry SF. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med. 1989;170:1627-33. (Pubitemid 19284562)
7. Hinshaw LB, Emerson TE Jr, Taylor FB Jr, Chang AC, Duerr M, Peer GT, Flournoy DJ, White GL, Kosanke SD, Murray CK. Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody. J Trauma. 1992;33:568-73.
8. Redl H, Schlag G, Ceska M, Davies J, Buurman WA. Interleukin-8 release in baboon septicemia is partially dependent on tumor necrosis factor. J Infect Dis. 1993;167:1464-6. (Pubitemid 23146206)
9. Rice TW, Bernard GR. Therapeutic intervention and targets for sepsis. Annu Rev Med. 2005;56:225-48. (Pubitemid 40299782)
10. Lorente JA, Marshall JC. Neutralization of tumor necrosis factor in preclinical models of sepsis. Shock. 2005;24(Suppl 1):107-19.
11. Eskandari MK, Bolgos G, Miller C, Nguyen DT, DeForge LE, Remick DG. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol. 1992;148:2724-30.
12. Evans GF, Snyder YM, Butler LD, Zuckerman SH. Differential expression of interleukin-1 and tumor necrosis factor in murine septic shock models. Circ Shock. 1989;29:279-90. (Pubitemid 20013182)
13. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987;330:662-4. (Pubitemid 18005583)
14. Leon LR, White AA, Kluger MJ. Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice. Am J Physiol. 1998;275:R269-77.
15. Qiu P, Cui X, Barochia A, Li Y, Natanson C, Eichacker PQ. The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death. Expert Opin Investig Drugs. 2011;20:1555-64.
16. Eichacker PQ, Parent C, Kalil A, Esposito C, Cui X, Banks SM, Gerstenberger EP, Fitz Y, Danner RL, Natanson C. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med. 2002;166:1197-205. (Pubitemid 35222596)
17. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991;10:4025-31. (Pubitemid 21905432)
18. Dinarello CA. The biology of interleukin 1 and comparison to tumor necrosis factor. Immunol Lett. 1987;16:227-31. (Pubitemid 18011299)
19. Sironi M, Gadina M, Kankova M, Riganti F, Mantovani A, Zandalasini M, Ghezzi P. Differential sensitivity of in vivo TNF and IL-6 production to modulation by anti-inflammatory drugs in mice. Int J Immunopharmacol. 1992;14:1045-50.
20. Morris PE, Zeno B, Bernard AC, Huang X, Das S, Edeki T, Simonson SG, Bernard GR. A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability, and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock. Crit Care. 2012;16:R31.
21. van der Poll T, van Deventer SJ. Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am. 1999;13:413-26. (Pubitemid 29248753)
22. Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab′)2, and Fab′ in mice. Cancer Res. 1986;46:3969-78. (Pubitemid 16075893)
23. Secher T, Vasseur V, Poisson DM, Mitchell JA, Cunha FQ, ves-Filho JC, Ryffel B. Crucial role of TNF receptors 1 and 2 in the control of polymicrobial sepsis. J Immunol. 2009;182:7855-64.
24. Ebach DR, Riehl TE, Stenson WF. Opposing effects of tumor necrosis factor receptor 1 and 2 in sepsis due to cecal ligation and puncture. Shock. 2005;23:311-8. (Pubitemid 40463623)
25. Lewis M, Tartaglia LA, Lee A, Bennett GL, Rice GC, Wong GH, Chen EY, Goeddel DV. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci USA. 1991;88:2830-4. (Pubitemid 21916513)
26. Marquez-Velasco R, Bojalil R, Buelna A, Flores-Guzman F, Estevez-Ramirez J, Laguna J, Hernandez AM, az-Quinonez A, Paniagua-Solis JF. Anti-tumor necrosis factor alpha F(ab′)2 antibody fragments protect in murine polymicrobial sepsis: concentration and early intervention are fundamental to the outcome. Inflamm Res. 2006;55:378-84. (Pubitemid 44825295)
27. Echtenacher B, Falk W, Mannel DN, Krammer PH. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol. 1990;145:3762-6.
28. Echtenacher B, Falk W, Mannel DN, Krammer PH. Survival from cecal ligation and puncture and the formation of fibrous adhesions in the peritoneal cavity depend on endogenous tumor necrosis factor. In: Faist E, Meakins JL, Schildberg FW, editors. Host Defense Dysfunction in Trauma, Shock and Sepsis. Berlin Heidelberg: Springer-Verlag; 1993. pp. 755-758.
29. Bernard GR, Francois B, Mira J-P, Vincent J-L, Dellinger RP, Russell JA, LaRosa SP, Laterre P-F, Levy MM, Dankner W, Schmitt N, Lindemann J, Wittebole X. Evaluating the efficacy and safety of two doses of the polyclonal anti-TNF-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled Phase IIb study. Crit Care Med. 2014; in press.
30. Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, Schorr C, Artigas A, Ramsay G, Beale R, Parker MM, Gerlach H, Reinhart K, Silva E, Harvey M, Regan S, Angus DC. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med. 2010;38:367-74.
31. ARISE; ANZICS APD Management Committee. The outcome of patients with sepsis and septic shock presenting to emergency departments in Australia and New Zealand. Crit Care Resusc. 2007;9:8-18.
32. Tidswell M, Tillis W, LaRosa SP, Lynn M, Wittek AE, Kao R, Wheeler J, Gogate J, Opal SM. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med. 2010;38:72-83.
33. Rice TW, Wheeler AP, Bernard GR, Vincent J-L, Angus DC, Aikawa N, Demeyer I, Sainati S, Amlot N, Cao C, Ii M, Matsuda H, Mouri K, Cohen J. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med. 2010;38:1685-94.
34. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gårdlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366:2055-64.
35. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, Donald-Smith GP, Gao H, Hennessy L, Finnerty CC, Lopez CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein BH, Miller-Graziano C, Calvano SE, Mason PH, Cobb JP, Rahme LG, Lowry SF, Maier RV, Moldawer LL, Herndon DN, Davis RW, Xiao W, Tompkins RG. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA. 2013;110:3507-12.
36. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013;13:260-8.
37. Remick DG, Call DR, Ebong SJ, Newcomb DE, Nybom P, Nemzek JA, Bolgos GE. Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality. Crit Care Med. 2001;29:473-81. (Pubitemid 32225286)